Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Recent News & Events
Near-term focus is the planned Q4 2026 NDA resubmission for cytisinicline, supported by positive 52-week ORCA-OL data and reiterated/initiated Buy ratings; sentiment is cautiously positive but tempered by a recent unexplained premarket dip.
Achieve presented 52-week ORCA-OL open-label data at CHEST 2026 showing 31.2% four-week sustained abstinence at Weeks 49-52, with quit rates rising through the year and 39.4% quitting among prior-placebo participants. The data support longer/repeat treatment courses, potentially expanding lifetime revenue per patient and reinforcing the NDA package ahead of resubmission.
H.C. Wainwright reiterates Buy, $12 target on ORCA-OL data
H.C. Wainwright reiterated a Buy rating and $12 price target following the 52-week ORCA-OL data, noting repeat treatment courses and longer durations could increase lifetime revenue per patient. The reiteration reinforces bullish analyst sentiment into the NDA resubmission.
Achieve plans to resubmit its cytisinicline NDA in Q4 2026 after a June 2026 Complete Response Letter limited to third-party manufacturing cGMP observations and labeling (no efficacy/safety deficiencies), with manufacturing transitioned to Adare. A near-term resubmission and potential H1 2027 approval are the key binary catalysts for the stock.
Stifel initiated coverage with a Buy rating and $18 price target, citing reduced risk from new manufacturing, leadership, strategy, and capital ahead of the NDA refiling. The initiation adds a fresh bullish voice and highlights substantial implied upside.
Benjamin Halladay appointed CFO effective October 5
Achieve appointed Benjamin Halladay (former Esperion CFO) as Chief Financial Officer, succeeding Mark Oki, and granted him inducement equity awards. The change brings new financial leadership ahead of the NDA resubmission and potential commercialization; impact is largely neutral near-term.
Shares slip 3% premarket with no company-specific catalyst
ACHV was indicated down ~3% premarket to $6.72 against a prior close of $6.93, with no company-specific catalyst identified and softness in the broader healthcare sector. The move reflects sentiment/flow rather than fundamentals but signals near-term volatility.